恩替卡韦联合水飞蓟宾对慢性乙型病毒性肝炎患者肝功能及肝纤维化指标的影响

Impact of Entecavir Combined with Silybinin on Liver Function and Hepatic Fibrosis Indicators of Patients with ChronicViral Hepatitis B

目的探讨恩替卡韦联合水飞蓟宾对慢性乙型病毒性肝炎患者肝功能及肝纤维化的影响。方法 200例慢性乙型病毒性肝炎患者依据治疗方式的不同分为两组各100例,观察组使用恩替卡韦联合水飞蓟宾治疗,对照组使用恩替卡韦治疗,比较两组的肝功能和肝纤维化指标。结果治疗6个月后,两组的ALT、 TBil、 AST、 HA、 IVC、 LN水平均显著低于治疗前,且观察组显著低于对照组(P <0.05)。结论恩替卡韦联合水飞蓟宾治疗慢性乙型病毒性肝炎患者能够有效缓解肝纤维化损伤,改善肝功能。

Objective To explore the impact of entecavir combined with silybinin on liver function and hepatic fibrosis of patients with chronic viral hepatitis B.Methods 200 patients with chronic viral hepatitis B were divided into two groups according to different treatment methods,with 100 cases in each group.The observation group was treated with entecavir combined with silybinin,and the control group was treated with entecavir.The liver function and liver fibrosis indicators were compared between two groups.Results After 6 months of treatment,the levels of ALT,TBil,AST,HA,IVC and LN in both groups were significantly lower than those before treatment,and the observation group was significantly lower than the control group(P<0.05).Conclusions Entecavir combined with silybinin in the treatment of patients with chronic viral hepatitis B can effectively alleviate liver fibrosis injury and improve liver function.